NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 8-K — Jul 31, 2026
Northwest Biotherapeutics entered into a $4.9 million convertible Promissory Note financing with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP. The note has a 12-month term, carries no interest, and includes a 5% original issue discount, with repayment due at maturity. In conjunction with the note, the company executed a new standby equity subscription agreement allowing it to draw up to $50 million over 24 months after the note is repaid or converted. This new agreement cancels the prior standby arrangement and is intended to provide a backstop for future funding needs associated with key milestones.
Key figures
- Debt Amount
- $4.9 million
- Interest Rate
- 0
- Note term
- 12 months
- Warrant amount
- $2 million
- Standby equity limit
- $50 million
- Warrant strike price
- $0.205 per share
- Original issue discount
- 5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.